Home » Nephrology » VA NEPHRON-D Trial: Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
VA NEPHRON-D trial

The VA NEPHRON-D trial tackled an important question about the combination therapy of ACEi and ARBs. We know from the RENAAL trial that losartan has significant benefits in diabetic nephropathy. The authors of the VA NEPHRON-D tiral aimed to assess if the addition of an ACE inhibitor to ARB therapy prevent eGFR reduction, ESRD, or death in patients with T2DM, CKD stage 2-3, and elevated urine albumin: creatinine. The trial included a reasonable number of 1448 patients who were randomized to losartan + placebo group and combination group of losartan and lisinopril. The trial was ended earlier due to inconclusive results. The authors of VA NEPHRON-D trial concluded that combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy. Source: NEJM

VA NEPHRON-D Trial: Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy